Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/2168479016680253 http://scihub22266oqcxt.onion/10.1177/2168479016680253 C5486404!5486404!28663940     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ther+Innov+Regul+Sci 2017 ; 51 (2): 146-52 Nephropedia Template TP {{tp|p=28663940|t=2017. Considerations for Use of Investigational Drugs in Public Health Emergencies |pdf=|usr=}}{{28663940}} gab.com Text Considerations for Use of Investigational Drugs in Public Health Emergencies JO: Ther Innov Regul Sci http://www.kidney.de/pget.php?&tw=1&pmid=28663940 #FOAvip The paradigm for the use of investigational drugs in public health emergencies has been recently tested to prevent and treat highly infectious and lethal diseases. Examples include the successful implementation of vaccine and therapeutic clinical trials during the recent Ebola outbreak in West Africa. On the other end of the spectrum was the Emergency Use Authorization (EUA) of peramivir in the treatment of H1N1 influenza virus that did not provide an opportunity to collect data or understand the effectiveness of the EUA program. Between the gold standard of a randomized controlled clinical trial and the problems associated with EUAs are the domain of expanded access protocols that may provide an avenue to make products available while awaiting licensure. This paper will examine the regulatory pathways in the United States (US) for the use of investigational drugs in a public health emergency as well as considerations when making these products available outside the US. Descriptions of the applications of the various approaches will be presented. Regardless of the pathway chosen, public health and clinical research planners need to work together to consider several factors associated with the respective options and maintain a goal of working toward the collection of data to support licensure before faced with future outbreaks. Finally, this paper will consider the lessons learned from public health response in the context of investigational drugs in other diseases where ?right to try laws? may pose opportunities, as well as challenges. Twit Text FOAVip Considerations for Use of Investigational Drugs in Public Health Emergencies ????Ther Innov Regul Sci http://www.kidney.de/pget.php?&tw=1&pmid=28663940 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28663940 #FOAvip English Wikipedia <ref>{{Cite pmid|28663940}}</ref> Considerations for Use of Investigational Drugs in Public Health Emergencies #MMPMID28663940 Kirchoff MC; Pierson JF Ther Innov Regul Sci 2017[Mar]; 51 (2): 146-52 PMID28663940show ga The paradigm for the use of investigational drugs in public health emergencies has been recently tested to prevent and treat highly infectious and lethal diseases. Examples include the successful implementation of vaccine and therapeutic clinical trials during the recent Ebola outbreak in West Africa. On the other end of the spectrum was the Emergency Use Authorization (EUA) of peramivir in the treatment of H1N1 influenza virus that did not provide an opportunity to collect data or understand the effectiveness of the EUA program. Between the gold standard of a randomized controlled clinical trial and the problems associated with EUAs are the domain of expanded access protocols that may provide an avenue to make products available while awaiting licensure. This paper will examine the regulatory pathways in the United States (US) for the use of investigational drugs in a public health emergency as well as considerations when making these products available outside the US. Descriptions of the applications of the various approaches will be presented. Regardless of the pathway chosen, public health and clinical research planners need to work together to consider several factors associated with the respective options and maintain a goal of working toward the collection of data to support licensure before faced with future outbreaks. Finally, this paper will consider the lessons learned from public health response in the context of investigational drugs in other diseases where ?right to try laws? may pose opportunities, as well as challenges. äConsiderations for Use of Investigational Drugs in Public Health Emerg(epmc).pdf DeepDyve Pubget Overpricing